Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human MAP3K8 Anticorps:
anti-Mouse (Murine) MAP3K8 Anticorps:
anti-Rat (Rattus) MAP3K8 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
role of p105 (Montrer CDH13 Anticorps)/Tpl2 signaling in lung homeostasis
rs1042058 GG Crohn's disease -risk polymorphism in TPL2 results in a gain-of-function by increasing TPL2 expression and signalling, thereby amplifying Pattern recognition receptor -initiated outcomes.
MAP3K8 is a direct target of miR (Montrer MLXIP Anticorps)-144-3p, and miR (Montrer MLXIP Anticorps)-144-3p downregulation is a factor in renal cell carcinoma (Montrer MOK Anticorps) progression through potentiation of MAP3K8 expression.
Taken together, these results suggest that Cot kinase might play a critical role in Helicobacter pylori type IV secretion apparatus-dependent early IL-8 (Montrer IL8 Anticorps) secretion and CagA (Montrer S100A8 Anticorps)-dependent late IL-8 (Montrer IL8 Anticorps) secretion as an alternative signaling molecule in the Erk (Montrer EPHB2 Anticorps) pathway.
Studies indicate that Tpl2, a MAP3K, participates in a broad range of cancer-related signaling pathways and induces tumorigenesis and progression of many cancers.
the results of the present study demonstrated that the miR (Montrer MLXIP Anticorps)-509-3p RCC (Montrer XRCC1 Anticorps) suppressor was a significant regulator of the MAP3K8 oncogene (Montrer RAB1A Anticorps), suggesting that it may have a potential therapeutic role in the treatment of renal cell carcinoma (Montrer MOK Anticorps)
findings provide a novel perspective on the role of the IL-33 (Montrer IL33 Anticorps)/ST2 (Montrer SULT2A1 Anticorps)/COT signaling pathway in supporting cancer-associated inflammation in the tumor microenvironment
structurally versatile active site significantly impacts the design of potent, low molecular weight COT kinase inhibitors
TPL2 mediates the phosphorylation of a fraction of nucleophosmin (Montrer NPM1 Anticorps) at threonine 199, an event required for its proteasomal degradation and maintenance of steady-state nucleophosmin (Montrer NPM1 Anticorps) levels.
MAP3K8 and miR-17-5p expression were inversely correlated with treatment response
study to determine whether Tpl2 influences the immune response generated to the extracellular bacterium Citrobacter rodentium, which induces a mixed Th1 (Montrer HAND1 Anticorps) and Th17 response; findings confirm the importance of Tpl2 in driving the development of the proinflammatory Th1 (Montrer HAND1 Anticorps) lineage as well as promoting IL-17A (Montrer IL17A Anticorps) expression and neutrophil recruitment during infection with extracellular bacteria
TPL-2-regulated Ccl24 (Montrer CCL24 Anticorps) in CD11c (Montrer ITGAX Anticorps)+CD11b (Montrer ITGAM Anticorps)+ cells prevents accelerated type-2 mediated immunity to H. polygyrus.
role of p105 (Montrer NEDD9 Anticorps)/Tpl2 signaling in lung homeostasis
this study shows that TPL-2 deficiency leads to severe house duct mite-induced airway allergy, when compared with wild-type mice
The kinase TPL2 activates ERK (Montrer EPHB2 Anticorps) and p38 (Montrer CRK Anticorps) signaling to promote neutrophilic inflammation
TPL2 kinase is a crucial signaling factor in iNKT cells and major mediator of hepatic inflammation.
Taken together this study identified that TPL-2 regulated TH2-mediated inflammation by supporting lipolysis and M2 macrophage activation, preventing TH2 cell expansion and downstream immunopathology and fibrosis.
Map3k8 decreases apoptosis of monocytes and enhances CCR2 (Montrer CCR2 Anticorps) expression on Ly6C(high)CD11c (Montrer ITGAX Anticorps)(low) monocytes of atherosclerotic ApoE (Montrer APOE Anticorps)(-/-) mice fed an high fat diet.
results demonstrate that Tpl2 promotes inflammation in part by constraining FoxP3 (Montrer FOXP3 Anticorps) expression and Treg immunosuppressive functions.
Tpl2 plays a significant role in promoting HCC (Montrer FAM126A Anticorps) development by its pro-inflammatory effect, which suggested that Tpl2 could be a molecular target for HCC (Montrer FAM126A Anticorps) prevention.
This gene is an oncogene that encodes a member of the serine/threonine protein kinase family. The encoded protein localizes to the cytoplasm and can activate both the MAP kinase and JNK kinase pathways. This protein was shown to activate IkappaB kinases, and thus induce the nuclear production of NF-kappaB. This protein was also found to promote the production of TNF-alpha and IL-2 during T lymphocyte activation. This gene may also utilize a downstream in-frame translation start codon, and thus produce an isoform containing a shorter N-terminus. The shorter isoform has been shown to display weaker transforming activity. Alternate splicing results in multiple transcript variants that encode the same protein.
mitogen-activated protein kinase kinase kinase 8
, Ewing sarcoma transformant
, cot (cancer Osaka thyroid) oncogene
, proto-oncogene c-Cot
, proto-oncogene serine/threoine protein kinase
, tumor progression locus 2
, COT proto-oncogene serine/threonine-protein kinase
, cancer Osaka thyroid oncogene
, cancer Osaka thyroid, oncogene
, mitogen activated protein kinase kinase kinase 8
, serine/threonine-protein kinase cot
, serine/threonine kinase (Tpl-2)